Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study
Background: Whether inflammation is independently associated with development of JAK2V617F mutation and myeloproliferative neoplasm is not clear. We tested the hypothesis that a loss-of-function polymorphism in IL6R (marked by rs4537545) reduces risk of JAK2V617F mutation and myeloproliferative neop...
Main Authors: | Kasper Mønsted Pedersen, Yunus Çolak, Christina Ellervik, Hans Carl Hasselbalch, Stig Egil Bojesen, Børge Grønne Nordestgaard |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-04-01
|
Series: | EClinicalMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537020300249 |
Similar Items
-
Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
by: Kasper Mønsted Pedersen, et al.
Published: (2020-05-01) -
Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
by: Kasper Mønsted Pedersen, et al.
Published: (2020-04-01) -
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals
by: Kasper Mønsted Pedersen, et al.
Published: (2020-09-01) -
Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
by: Christoph Garbers, et al.
Published: (2020-05-01) -
JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
by: Fanti Saktini, et al.
Published: (2015-12-01)